GBMT

GBM Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative treatments for glioblastoma multiforme (GBM), one of the most aggressive and difficult-to-treat forms of brain cancer. The company's lead candidate, GBM-001, is a novel, brain-penetrant small molecule designed to inhibit tubulin polymerization, thereby disrupting tumor cell division. Currently being evaluated in Phase 2 clinical trials, GBM-001 aims to overcome the limitations of existing therapies by effectively crossing the blood-brain barrier. GBM Therapeutics focuses on addressing the high unmet medical need in neuro-oncology through targeted therapeutic strategies. The company maintains a specialized focus on advancing its lead program toward commercialization to improve outcomes for patients with primary brain tumors.